In addition to cases of primary resistance, the emergence of de novo KRAS mutations has also been linked to acquired resistance in multiple cancer types and contexts: to both anti-EGFR therapy and MEK1/2 inhibitors in CRC13,14, to imatinib in chronic myelogenous leukaemia15, and to BRAF/MEK inhibitors in melanoma16. Here, EGFR is linked to cancer.